Literature DB >> 16303099

The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma.

A J Kwartz1, D B Henson, R A Harper, A F Spencer, D McLeod.   

Abstract

OBJECTIVES: To determine the potential of optic nerve head tomography [Heidelberg Retina Tomograph (HRT)] and scanning laser polarimetry (GDx) for identifying patients with glaucomatous visual field loss.
DESIGN: Examinations were performed with the HRT, GDx and Humphrey Field Analyzer (HFA). Glaucoma was defined by the presence of a field defect. Patients within the cross-sectional groups underwent a single examination, whereas patients in the longitudinal groups were examined 6 monthly, for an average of 3.5 years.
SETTING: Manchester Royal Eye Hospital, UK. PARTICIPANTS: Patients with primary open angle glaucoma (POAG) or who were at risk of developing glaucoma.
INTERVENTIONS: The diagnostic accuracies of the HRT and GDx were compared; specificity was set at 95%. The rate of change was determined by linear regression. To estimate the clinical application of the instruments, the proportion of an unselected group of patients on whom the examinations could be performed was calculated. Additionally, the time taken to perform and process each examination was measured. MAIN OUTCOME MEASURES: The ability of the techniques to identify cases showing deterioration. The level of agreement and applicability of the techniques. Time taken to perform and process each examination.
RESULTS: From the cross-sectional group, the maximum sensitivities of the HRT and GDx were 59% and 45%, respectively (at 95% specificity). From the two longitudinal cohorts, the level of agreement between the three instruments for identification of the development and deterioration of POAG was low. The applicability of the techniques was 80% (HRT), 88% (GDx) and 98% (HFA). The length of time to perform a full examination with each instrument was 12.3, 11.8 and 28.3 minutes, respectively. Agreement of HRT and GDx parameters between and within observers was largely good.
CONCLUSIONS: There is poor agreement for detection of glaucoma between the HFA, HRT and GDx. The techniques are amenable to use in the clinical environment, but no single examination has sufficient diagnostic precision to be used in isolation; also, the imaging techniques were not universally applicable. Neither the HRT nor GDx should be viewed as a replacement for visual field examination. Further research is needed into why most patients within the longitudinal arms of the study showed very little deterioration and into determining aspects of the structure versus function relationship in glaucoma that may explain why any one technique fails to detect a proportion of cases.

Entities:  

Mesh:

Year:  2005        PMID: 16303099     DOI: 10.3310/hta9460

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  5 in total

Review 1.  The future of glaucoma clinics.

Authors:  A M S Morley; I Murdoch
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

Review 2.  Optic nerve head and fibre layer imaging for diagnosing glaucoma.

Authors:  Manuele Michelessi; Ersilia Lucenteforte; Francesco Oddone; Miriam Brazzelli; Mariacristina Parravano; Sara Franchi; Sueko M Ng; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

3.  p107 in the public eye: an Rb understudy and more.

Authors:  Stacey E Wirt; Julien Sage
Journal:  Cell Div       Date:  2010-04-02       Impact factor: 5.130

4.  Detecting abnormality in optic nerve head images using a feature extraction analysis.

Authors:  Haogang Zhu; Ali Poostchi; Stephen A Vernon; David P Crabb
Journal:  Biomed Opt Express       Date:  2014-06-11       Impact factor: 3.732

5.  Cost-effectiveness analysis of confocal scan laser ophthalmoscope (HRT II) versus GDX for diagnosing glaucoma.

Authors:  Mahdi Mokhtari-Payam; Maziar Moradi-Lakeh; Mohsen Yaghoubi; Mohammad Moradijou
Journal:  J Curr Ophthalmol       Date:  2015-11-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.